Date: 2016-12-14
Type of
information: Initiation of development program
phase:
Announcement: initiation of development program
Company: Medivir (Sweden)
Product: MIV-323
Action
mechanism:
- fusion inhibitor. MIV-323 is small molecule inhibitor of the RSV fusion (RSV F) protein. The RSV F protein is required for the virus to enter cells of the respiratory tract, and is a clinically- validated RSV target. Inhibiting the activity of the F protein will result in reduction of the severity and incidence of RSV- associated disease caused by RSV infections of the human upper and lower respiratory tract.
- Medivir entered a license agreement with Boehringer Ingelheim for exclusive, global rights to a drug program for the treatment and prevention of RSV infection in August 2014. The RSV fusion protein inhibitor project was in the discovery phase. Medivir scientists have optimized the properties of these early molecules, resulting in the selection of MIV-323 as a candidate drug in late 2016.
Disease: Respiratory Syncytial Virus (RSV) infection
Therapeutic
area: Infectious diseases
Country:
Trial
details:
Latest
news: • On December 14, 2016, Medivir announced that MIV-323 has been selected as a candidate drug from its fusion inhibitor project for the treatment of respiratory syncytial virus (RSV) infection, and has now entered non-clinical development. The overall aim for the project is to find a partner for the clinical development and marketing of the project.
.
Is
general: Yes
